1. LBA4 Preliminary safety and efficacy of adagrasib with pembrolizumab in treatment-naïve patients with advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. (December 2022) Authors: Jänne, P.A.; Smit, E.F.; de Marinis, F.; Laskin, J.; Gomez, M. Domine; Gadgeel, S.; Garassino, M.C.; Lu, S.; Spira, A.S.; Kang, V.; Roshan, S.; Yan, X.; Felip, E. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗